Alzamend Neuro partners with Massachusetts General Hospital for a Phase II clinical trial of AL001
- Alzamend Neuro collaborates with Massachusetts General Hospital to conduct a Phase II clinical trial of AL001 for Alzheimer's patients.
- The trial will compare lithium levels in the brain between Alzheimer's patients and healthy subjects.
- Dr. Ovidiu Andronesi from Harvard University will be the principal investigator.
- The study aims to meet regulatory safety standards for FDA approval through the Section 505(b)(2) pathway.
Read more
First patient enrollment in the U.S. - A milestone for the global multi-center phase â…¢ clinical trial of telitacicept for myasthenia gravis
- RemeGen's telitacicept has achieved first patient enrollment in the U.S. for its global phase III trial for generalized myasthenia gravis (gMG).
- The trial is a multicenter, randomized, double-blind, placebo-controlled study aiming to recruit 180 patients globally.
- Telitacicept targets BLyS and APRIL, reducing pathogenic antibodies and improving clinical status in gMG patients.
- Previously granted orphan drug and fast track status by the FDA and breakthrough therapy designation by China's NMPA.
Read more
ProMIS Neurosciences announces data on the pathogenic role of toxic misfolded SOD1 aggregates in ALS
- ProMIS Neurosciences published two papers on the role of toxic misfolded SOD1 aggregates in ALS.
- The Acta Neuropathologica paper reports on the presence of aggregated SOD1 seeds in both familial and sporadic ALS.
- The Open Biology paper highlights the importance of amyloidogenic regions in β-strands II and III in SOD1 aggregation and toxicity.
- These findings support targeting misfolded SOD1 as a therapeutic strategy and potential biomarker for ALS.
Read more
SEED Therapeutics enters into strategic research collaboration with Eisai
- SEED and Eisai will collaborate to discover and develop novel molecular glue degraders for neurodegeneration and oncology.
- SEED will receive up to $1.5 billion in upfront and milestone payments, plus tiered royalties.
- Eisai will have exclusive rights to develop and commercialize compounds from the collaboration.
- SEED concurrently launched Series A-3 financing, raising $24 million with a second close targeted for Q4 2024.
Read more
Cognigenics announces groundbreaking publication on shRNA treatment for 5-HT2A receptor knockdown
- Cognigenics published research on using shRNA to knockdown the 5-HT2A receptor, improving memory and reducing neural excitability.
- The study demonstrated significant cognitive improvements and neuronal stability in both in vivo and in vitro models.
- This approach could lead to novel treatments for neurocognitive and neuropsychiatric diseases.
- Cognigenics aims to develop long-term, noninvasive genetic treatments with minimal side effects.
Read more
Neumora Therapeutics reports second quarter 2024 financial results and provides business update
- Phase 3 data from KOASTAL-1 study of navacaprant in major depressive disorder (MDD) expected in Q4 2024.
- Progressing clinical studies in MDD, bipolar depression, and Alzheimer’s disease agitation.
- Strong financial position with $371.6 million in cash, cash equivalents, and marketable securities.
- Research and development expenses increased to $48.6 million in Q2 2024 from $32.8 million in Q2 2023.
Read more
Levicept announces positive results of phase II trial of novel neurotrophin-3 inhibitor, LEVI-04, for the treatment of patients with moderate to severe osteoarthritis
- Phase II trial of LEVI-04 met all primary and secondary efficacy endpoints, showing significant analgesia across all measures for all doses.
- The study enrolled over 510 participants with knee osteoarthritis and was conducted across Europe and Hong Kong.
- LEVI-04 demonstrated a greater than 50% reduction in WOMAC pain scores from baseline at Week 17 for all doses.
- The treatment was well tolerated with no increase in incidence of rapidly progressive osteoarthritis compared to placebo.
Read more
